UroGen Pharma Ltd. (URGN) carries a Roarable Rating of E (Strong Sell) with 24/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, UroGen Pharma Ltd. (NASDAQ: URGN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $33.48 (-0.80% 1D, market cap $1.64B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, URGN ranks #951 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), URGN carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of 88.7%, and ROIC of -35.0%. By comparison, RARE (Ultragenyx Pharmaceutical Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $1.65B) and OCUL (Ocular Therapeutix Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $1.61B). Among the 5-stock peer group, ANIP leads on earnings multiple (21.5x) while ANIP leads on capital efficiency (16.0% ROIC).
Per URGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001668243), UroGen Pharma Ltd. generated $109.8M in revenue (+21.4% YoY), -$153.5M in net income, and -$162.7M in free cash flow against $200.5M in total assets and $122.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 49% of 52W Range • RSI-14 at 32.2 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±11% realized swing band)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While URGN currently carries a cautious 24/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($40.17) and Max Pain ($35.15) forces dealer call-delta covering toward $53.35.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
UroGen Pharma Ltd. (URGN) slipped -0.80% to $33.48, trading at 49% of its 52-week range ($16.5 – $50.81). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Five-year Olympus follow-up data published in Therapeutic Advances in Urology reinforce the long-term durability of response with JELMYTOResults demonstrate sustained disease control through extended follow-up among pati
Five-year Olympus follow-up data published in Therapeutic Advances in Urology reinforce the long-term durability of response with JELMYTOResults demonstrate sustained disease control through extended follow-up among
Conference Call and Webcast Scheduled for Wednesday, November 4th, 2026, at 10:00 AM ETPRINCETON, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and c
UroGen Pharma (URGN) just hit a key regulatory milestone. The FDA accepted its New Drug Application for UGN-103 for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, with a PDUFA decision date set
PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $75 price target.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +21.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on URGN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for URGN. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, UroGen Pharma Ltd. (URGN) ranks #951 by composite RQD confidence (24/100, grade E) and #296 by equity capitalization ($1.64B). Within this direct 5-issuer industry benchmark cohort, ANIP leads on earnings valuation at 21.5x trailing P/E, while ANIP leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. ANIP currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with URGN at 24/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| URGN
ACTIVE
UroGen Pharma Ltd. | E | 24/100 | — | 88.7% | -35.0% | -0.80% | $1.64B | Benchmark Subject |
| RARE Ultragenyx Pharmaceutical Inc. | E | 26/100 | — | — | -35.0% | -2.44% | $1.65B | /rare-vs-urgn → |
| OCUL Ocular Therapeutix Inc. | E | 25/100 | — | 87.3% | -35.0% | +0.27% | $1.61B | /ocul-vs-urgn → |
| NUVB Nuvation Bio Inc. (Class A) | E | 19/100 | — | — | -35.0% | +3.92% | $1.67B | /nuvb-vs-urgn → |
| ANIP ANI Pharmaceuticals Inc. | C | 64/100 | 21.5x | — | 16.0% | +2.02% | $1.68B | /anip-vs-urgn → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), UroGen Pharma Ltd. (URGN) reported GAAP revenue of $109.8M (+21.4% vs. FY2024 revenue of $90.4M , and +32.7% cumulative change since FY2023) , GAAP net income of -$153.5M, operating cash flow of -$162.4M, and free cash flow of -$162.7M (-67.7% YoY). On the balance sheet, URGN closed FY2025 with $200.5M in total assets against $122.2M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $109.8M | -$153.5M | -$162.4M | -$162.7M | $200.5M | $122.2M |
| FY2024 (FY) | 2024-12-31 | $90.4M | -$126.9M | -$96.8M | -$97.1M | $285.7M | $121.7M |
| FY2023 (FY) | 2023-12-31 | $82.7M | -$102.2M | -$76.4M | -$76.4M | — | — |
As of 2026-11-02, UroGen Pharma Ltd. (NASDAQ: URGN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $33.48 (-0.80% 1D, market cap $1.64B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, URGN ranks #951 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), URGN carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of 88.7%, and ROIC of -35.0%. By comparison, RARE (Ultragenyx Pharmaceutical Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $1.65B) and OCUL (Ocular Therapeutix Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $1.61B). Among the 5-stock peer group, ANIP leads on earnings multiple (21.5x) while ANIP leads on capital efficiency (16.0% ROIC).
Per URGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001668243), UroGen Pharma Ltd. generated $109.8M in revenue (+21.4% YoY), -$153.5M in net income, and -$162.7M in free cash flow against $200.5M in total assets and $122.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
URGN last traded at $33.48 (-0.80% on volume of 1,439,373 shares), positioning the stock -16.65% below its 50-day simple moving average ($40.17) and +6.69% above its 200-day simple moving average ($31.38). Across its 52-week range of $16.50 to $50.81, URGN sits at the 49.5% percentile with a 14-day RSI of 32.2 (NEUTRAL RANGE) and an implied next-earnings move of ±11.0% ($29.80 to $37.16).
Why URGN Stock slipped -0.80% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).